Adaptive Biotechnologies Corp (NASDAQ: ADPT) saw its stock price surge 5.98% in after-hours trading on Thursday, following the release of its first-quarter 2025 financial results that surpassed analysts' expectations.
The biotechnology company reported a quarterly loss of $0.20 per share, significantly better than the analyst consensus estimate of a $0.31 loss. This represents a 35.48% beat on expectations and a 39.39% improvement from the $0.33 loss per share reported in the same quarter last year. Revenue for the quarter came in at $52.44 million, beating the analyst estimate of $42.7 million by 22.77% and showing a 25.14% increase from the $41.87 million reported in the prior-year period.
Adaptive Biotechnologies also provided a positive outlook for the full year, expecting revenue for its MRD (Minimal Residual Disease) business to be between $180 million and $190 million. The company anticipates full-year total operating expenses, including cost of revenue, to be between $335 million and $345 million, with a total company cash burn expected to be between $50 million and $60 million. These figures suggest that the company is managing its growth and expenses effectively, which likely contributed to investor optimism and the subsequent stock price increase.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.